| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.4 | 5e-20 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | 0.27 | 9e-08 |
| mRNA | BRD-K04800985 | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-07 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | 0.28 | 3e-07 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-06 |
| mRNA | Sildenafil | CTRPv2 | pan-cancer | AAC | 0.16 | 1e-05 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.15 | 1e-05 |
| mRNA | BRD-K90370028 | CTRPv2 | pan-cancer | AAC | 0.23 | 1e-05 |
| mRNA | PF-4800567 hydrochloride | CTRPv2 | pan-cancer | AAC | 0.22 | 2e-05 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | 0.15 | 5e-05 |